AstraZeneca, Roche to Develop CDx for NSCLC | GenomeWeb

NEW YORK (GenomeWeb) – AstraZeneca today announced a collaboration with Roche to develop a companion diagnostic for AstaZeneca's investigational compound for non-small cell lung cancer.

The test will be directed at AZD9291 and will be developed to identify epidermal growth factor receptor mutations in tumor tissue as well as plasma samples from patients with NSCLC. It also will be designed to optimize the clinical development of AZD9291 for patients who are resistant to first-generation EGFR tyrosine kinase inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.